归海绝山
Lv5
990 积分
2021-05-24 加入
-
A Randomized Phase II Trial of Pemetrexed-Cisplatin Plus Bevacizumab or Thoracic Radiotherapy Followed by Surgery for Stage IIIA (N2) Non-Squamous Non-Small Cell Lung Cancer
8个月前
已关闭
-
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
8个月前
已完结
-
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
8个月前
已完结
-
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
8个月前
已完结
-
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
8个月前
已关闭
-
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
8个月前
已完结
-
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
8个月前
已完结
-
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
8个月前
已关闭
-
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
9个月前
已完结
-
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
9个月前
已完结